

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>PFIZER INC</u>  (Last) (First) (Middle) 235 E 42ND ST  (Street) NEW YORK NY 10017  (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>SpringWorks Therapeutics, Inc. [ SWTX ]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director <input checked="" type="checkbox"/> 10% Owner  Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) 09/17/2019	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	09/17/2019		C		978,194 <sup>(1)</sup>	A	(1)	978,194	D <sup>(5)</sup>	
Common Stock	09/17/2019		C		3,039,051 <sup>(2)</sup>	A	(2)	4,017,245	D <sup>(5)</sup>	
Common Stock	09/17/2019		C		526,602 <sup>(3)</sup>	A	(3)	4,543,847	D <sup>(5)</sup>	
Common Stock	09/17/2019		P		50,000 <sup>(4)</sup>	A	\$18	4,593,847	D <sup>(5)</sup>	

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Junior Series A Convertible Preferred Stock	(1)	09/17/2019		C			6,437,500	(1)	(1)	Common Stock	978,194 <sup>(1)</sup>	\$0	0	D <sup>(5)</sup>	
Series A Convertible Preferred Stock	(2)	09/17/2019		C			20,000,000	(2)	(2)	Common Stock	3,039,051 <sup>(2)</sup>	\$0	0	D <sup>(5)</sup>	
Series B Convertible Preferred Stock	(3)	09/17/2019		C			3,465,571	(3)	(3)	Common Stock	526,602 <sup>(3)</sup>	\$0	0	D <sup>(5)</sup>	

1. Name and Address of Reporting Person* <u>PFIZER INC</u>  (Last) (First) (Middle) 235 E 42ND ST  (Street) NEW YORK NY 10017  (City) (State) (Zip)		
--	--	--

1. Name and Address of Reporting Person\*

[Pfizer Ventures \(US\) LLC](#)

(Last) (First) (Middle)

[235 EAST 42ND STREET](#)

(Street)

[NEW YORK NY 10017](#)

(City) (State) (Zip)

**Explanation of Responses:**

1. Each share of Junior Series A Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 6.5810:1 basis upon the closing of the Issuer's initial public offering for no additional consideration. The Junior Series A Convertible Preferred Stock had no expiration date. Such shares are held of record by Pfizer Inc. ("Pfizer").
2. Each share of Series A Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 6.5810:1 basis upon the closing of the Issuer's initial public offering for no additional consideration. The Series A Convertible Preferred Stock had no expiration date. Such shares are held of record by Pfizer.
3. Each share of Series B Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 6.5810:1 basis upon the closing of the Issuer's initial public offering for no additional consideration. The Series B Convertible Preferred Stock had no expiration date. Such shares are held of record by Pfizer Ventures (US) LLC, a wholly-owned subsidiary of Pfizer ("PVUS").
4. PVUS purchased such additional shares of Common Stock in the Issuer's initial public offering at the initial public offering price of \$18.00 per share.
5. Each Reporting Person disclaims ownership of securities held by the other Reporting Person, except to the extent of its pecuniary interest therein.

[Pfizer Inc., By /s/ Susan Grant,](#) 09/19/2019  
[Assistant Secretary](#)

[Pfizer Ventures \(US\) LLC By](#) 09/19/2019  
[/s/ Susan Grant, Secretary](#)

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**